Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.
AGAMREE — CATALYST PHARMS, approved 2024-06-05 (NDA215239).
989 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.